How Gilead’s New Hepatitis C Virus Combination Stacks Up to the Competition

Gilead's pan-genotypic hepatitis C virus combo, Epclusa, could significantly boost the company's sales by filling some important niches. Antiviral champ Gilead Sciences  recently earned FDA approval for another hepatitis C virus (HCV) combination treatment, Epclusa. Epclusa is poised to boost Gilead's numbers by filling an important niche that has been somewhat overlooked, and Bristol-Myers Squibb  is about to lose hundreds of millions annually in the